<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02882854</url>
  </required_header>
  <id_info>
    <org_study_id>160282</org_study_id>
    <nct_id>NCT02882854</nct_id>
  </id_info>
  <brief_title>Guanfacine for PONV and Pain After Sinus Surgery</brief_title>
  <official_title>Guanfacine for PONV and Pain After Sinus Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative nausea and vomiting (PONV) and pain are the most common causes of Post
      Anesthesia Care Unit (PACU) discharge delay, with untreated PONV occurring in 20-30% of
      post-surgical patients. The effect of guanfacine (GF) administration on pain and nausea
      scores will be assessed with two groups. One group will receive 1 mg of GF to take orally and
      the other group will receive a similar appearing placebo (containing no drug) to take orally.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain after surgery is commonly treated with narcotics which can potentiate PONV, further
      delaying PACU discharge. In multiple studies, alpha-2 agonists such as clonidine and
      dexmedetomidine reduce both the incidence of PONV and post-op pain, as well as requirements
      for postoperative analgesics. These actions are mediated via central alpha-2A receptors
      (A2AR). Of the A2AR agonists, guanfacine, though a weak antihypertensive agent, has the
      highest selectivity for the A2AR, but to date is untested for its potential to treat either
      PONV or post-operative pain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of PONV Score of Assessments Done at 15 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS)</measure>
    <time_frame>15 minutes after arriving in PACU</time_frame>
    <description>Comparison of PONV Score of assessments done at 15 minutes after arrival in PACU using the nVRS when 0 is no nausea and 10 is worst nausea</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of PONV Score of Assessments Done at 30 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS)</measure>
    <time_frame>30 minutes after arriving in PACU</time_frame>
    <description>Comparison of PONV Score of assessments done at 30 minutes after arrival in PACU using the nVRS when 0 is no nausea and 10 is worst nausea</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of PONV Score of Assessments Done at 60 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS)</measure>
    <time_frame>60 minutes after arriving in PACU</time_frame>
    <description>Comparison of PONV Score of assessments done at 60 minutes after arrival in PACU using the nVRS when 0 is no nausea and 10 is worst nausea</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Nausea Assessment Using 11-point Nausea Scale (nVRS)</measure>
    <time_frame>24 hours post op</time_frame>
    <description>PONV assessed using nVRS at 24 hours postop when 0 is no nausea and 10 is worst nausea.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Postoperative Pain Assessment Using 11-point Visual/Verbal Analog (VAS)</measure>
    <time_frame>15, 30, 60 minutes after arriving in PACU</time_frame>
    <description>Maximum postoperative pain assessment assessed in PACU at 15, 30 and 60 minutes after PACU arrival using VAS when 0 is no pain and 10 is worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Pain Assessment Using 11-point Visual/Verbal Analog (VAS)</measure>
    <time_frame>24 hours postop</time_frame>
    <description>Postoperative pain assessment using VAS at 24 hours postop when 0 is no pain and 10 is worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Narcotic Requirement in PACU</measure>
    <time_frame>Time frame between arrival and discharge in PACU, approximately 90 minutes</time_frame>
    <description>Total narcotic requirement in PACU tallied in morphine equivalents during PACU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Doses of PONV Treatment Administered in PACU</measure>
    <time_frame>Time frame between arrival and discharge in PACU, approximately 90 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PACU Length of Stay in Minutes</measure>
    <time_frame>Time frame between arrival and discharge in PACU, approximately 90 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Guanfacine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Guanfacine 1 mg capsule by mouth, one time prior to surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with a similar appearance to guanfacine by mouth one time prior to surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guanfacine</intervention_name>
    <description>Patients will receive 1 mg of guanfacine to take orally.</description>
    <arm_group_label>Guanfacine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  VUMC patients undergoing sinus surgery in MCE OR

        Exclusion Criteria:

          -  Inability to read and freely consent

          -  Patients who take alpha-2 agonists routinely (guanfacine, clonidine, tizanidine)

          -  Patients undergoing sinus surgery planned for greater than 3 hours

          -  Patients with significant pre-existing pain, on chronic pain (opioid, methadone)
             therapy, severe fibromyalgia or other pre-existing pain condition in any body part

          -  Patients with preoperative nausea/vomiting at baseline.

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen T Harvey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dolin SJ, Cashman JN, Bland JM. Effectiveness of acute postoperative pain management: I. Evidence from published data. Br J Anaesth. 2002 Sep;89(3):409-23. Review.</citation>
    <PMID>12402719</PMID>
  </reference>
  <reference>
    <citation>Luttinger D, Ferrari R, Perrone MH, Haubrich DR. Pharmacological analysis of alpha-2 adrenergic mechanisms in nociception and ataxia. J Pharmacol Exp Ther. 1985 Mar;232(3):883-9.</citation>
    <PMID>2857790</PMID>
  </reference>
  <reference>
    <citation>Yamadera H, Ferber G, Matejcek M, Pokorny R. Electroencephalographic and psychometric assessment of the CNS effects of single doses of guanfacine hydrochloride (Estulic) and clonidine (Catapres). Neuropsychobiology. 1985;14(2):97-107.</citation>
    <PMID>3911096</PMID>
  </reference>
  <reference>
    <citation>Connor DF, Arnsten AF, Pearson GS, Greco GF. Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents. Expert Opin Pharmacother. 2014 Aug;15(11):1601-10. doi: 10.1517/14656566.2014.930437. Epub 2014 Jul 3. Review.</citation>
    <PMID>24992513</PMID>
  </reference>
  <reference>
    <citation>Massad IM, Mohsen WA, Basha AS, Al-Zaben KR, Al-Mustafa MM, Alghanem SM. A balanced anesthesia with dexmedetomidine decreases postoperative nausea and vomiting after laparoscopic surgery. Saudi Med J. 2009 Dec;30(12):1537-41.</citation>
    <PMID>19936416</PMID>
  </reference>
  <reference>
    <citation>Kamibayashi T, Hayashi Y, Mammoto T, Yamatodani A, Sumikawa K, Yoshiya I. Role of the vagus nerve in the antidysrhythmic effect of dexmedetomidine on halothane/epinephrine dysrhythmias in dogs. Anesthesiology. 1995 Nov;83(5):992-9.</citation>
    <PMID>7486186</PMID>
  </reference>
  <reference>
    <citation>Unnerstall JR, Kopajtic TA, Kuhar MJ. Distribution of alpha 2 agonist binding sites in the rat and human central nervous system: analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents. Brain Res. 1984 Mar;319(1):69-101. Review.</citation>
    <PMID>6324960</PMID>
  </reference>
  <reference>
    <citation>Giovannoni MP, Ghelardini C, Vergelli C, Dal Piaz V. Alpha2-agonists as analgesic agents. Med Res Rev. 2009 Mar;29(2):339-68. doi: 10.1002/med.20134. Review.</citation>
    <PMID>18680204</PMID>
  </reference>
  <reference>
    <citation>Aghajanian GK, Wang YY. Common alpha 2- and opiate effector mechanisms in the locus coeruleus: intracellular studies in brain slices. Neuropharmacology. 1987 Jul;26(7B):793-9. Review.</citation>
    <PMID>2443865</PMID>
  </reference>
  <reference>
    <citation>Ittermann T, Völzke H, Baumeister SE, Appel K, Grabe HJ. Diagnosed thyroid disorders are associated with depression and anxiety. Soc Psychiatry Psychiatr Epidemiol. 2015 Sep;50(9):1417-25. doi: 10.1007/s00127-015-1043-0. Epub 2015 Mar 17.</citation>
    <PMID>25777685</PMID>
  </reference>
  <reference>
    <citation>Baser E, Togrul C, Ozgu E, Esercan A, Caglar M, Gungor T. Effect of pre-procedural state-trait anxiety on pain perception and discomfort in women undergoing colposcopy for cervical cytological abnormalities. Asian Pac J Cancer Prev. 2013;14(7):4053-6.</citation>
    <PMID>23991951</PMID>
  </reference>
  <reference>
    <citation>Benarroch EE. The locus ceruleus norepinephrine system: functional organization and potential clinical significance. Neurology. 2009 Nov 17;73(20):1699-704. doi: 10.1212/WNL.0b013e3181c2937c.</citation>
    <PMID>19917994</PMID>
  </reference>
  <reference>
    <citation>Goldman-Rakic PS. Cellular basis of working memory. Neuron. 1995 Mar;14(3):477-85. Review.</citation>
    <PMID>7695894</PMID>
  </reference>
  <reference>
    <citation>Wang M, Gamo NJ, Yang Y, Jin LE, Wang XJ, Laubach M, Mazer JA, Lee D, Arnsten AF. Neuronal basis of age-related working memory decline. Nature. 2011 Jul 27;476(7359):210-3. doi: 10.1038/nature10243.</citation>
    <PMID>21796118</PMID>
  </reference>
  <reference>
    <citation>Goldman-Rakic PS. Circuitry of the frontal association cortex and its relevance to dementia. Arch Gerontol Geriatr. 1987 Sep;6(3):299-309. Review.</citation>
    <PMID>3318747</PMID>
  </reference>
  <reference>
    <citation>Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995 Jan;34(1):50-4.</citation>
    <PMID>7860456</PMID>
  </reference>
  <reference>
    <citation>Arnsten AF, Jin LE. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med. 2012 Mar;85(1):45-58. Epub 2012 Mar 29. Review.</citation>
    <PMID>22461743</PMID>
  </reference>
  <reference>
    <citation>Zhao X, Tong D, Long B, Wu X. [Effects of different doses of dexmedetomidine on the recovery quality from general anesthesia undergoing thyroidectomy]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014 Apr;26(4):239-43. doi: 10.3760/cma.j.issn.2095-4352.2014.04.008. Chinese.</citation>
    <PMID>24709495</PMID>
  </reference>
  <reference>
    <citation>Blaudszun G, Lysakowski C, Elia N, Tramèr MR. Effect of perioperative systemic α2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials. Anesthesiology. 2012 Jun;116(6):1312-22. doi: 10.1097/ALN.0b013e31825681cb. Review.</citation>
    <PMID>22546966</PMID>
  </reference>
  <reference>
    <citation>Lin TF, Yeh YC, Lin FS, Wang YP, Lin CJ, Sun WZ, Fan SZ. Effect of combining dexmedetomidine and morphine for intravenous patient-controlled analgesia. Br J Anaesth. 2009 Jan;102(1):117-22. doi: 10.1093/bja/aen320. Epub 2008 Nov 5.</citation>
    <PMID>18987053</PMID>
  </reference>
  <reference>
    <citation>Gurbet A, Basagan-Mogol E, Turker G, Ugun F, Kaya FN, Ozcan B. Intraoperative infusion of dexmedetomidine reduces perioperative analgesic requirements. Can J Anaesth. 2006 Jul;53(7):646-52.</citation>
    <PMID>16803911</PMID>
  </reference>
  <reference>
    <citation>Ozkose Z, Demir FS, Pampal K, Yardim S. Hemodynamic and anesthetic advantages of dexmedetomidine, an alpha 2-agonist, for surgery in prone position. Tohoku J Exp Med. 2006 Oct;210(2):153-60.</citation>
    <PMID>17023769</PMID>
  </reference>
  <reference>
    <citation>Tufanogullari B, White PF, Peixoto MP, Kianpour D, Lacour T, Griffin J, Skrivanek G, Macaluso A, Shah M, Provost DA. Dexmedetomidine infusion during laparoscopic bariatric surgery: the effect on recovery outcome variables. Anesth Analg. 2008 Jun;106(6):1741-8. doi: 10.1213/ane.0b013e318172c47c.</citation>
    <PMID>18499604</PMID>
  </reference>
  <reference>
    <citation>Rago R, Forfori F, Materazzi G, Abramo A, Collareta M, Miccoli P, Giunta F. Evaluation of a preoperative pain score in response to pressure as a marker of postoperative pain and drugs consumption in surgical thyroidectomy. Clin J Pain. 2012 Jun;28(5):382-6. doi: 10.1097/AJP.0b013e3182326495.</citation>
    <PMID>22001665</PMID>
  </reference>
  <reference>
    <citation>Hicks JA, Jenkins JG. The measurement of preoperative anxiety. J R Soc Med. 1988 Sep;81(9):517-9.</citation>
    <PMID>3184108</PMID>
  </reference>
  <reference>
    <citation>Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008 Dec;61(12):1234-1240. doi: 10.1016/j.jclinepi.2008.01.006. Epub 2008 Jul 10.</citation>
    <PMID>18619805</PMID>
  </reference>
  <reference>
    <citation>Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999 Sep;91(3):693-700.</citation>
    <PMID>10485781</PMID>
  </reference>
  <reference>
    <citation>Aubrun F, Langeron O, Quesnel C, Coriat P, Riou B. Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous morphine titration. Anesthesiology. 2003 Jun;98(6):1415-21.</citation>
    <PMID>12766651</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <results_first_submitted>November 20, 2018</results_first_submitted>
  <results_first_submitted_qc>December 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 3, 2019</results_first_posted>
  <last_update_submitted>December 13, 2018</last_update_submitted>
  <last_update_submitted_qc>December 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Stephen Harvey</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guanfacine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 10, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT02882854/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Guanfacine</title>
          <description>Guanfacine 1 mg capsule by mouth, one time prior to surgery.
Guanfacine: Patients will receive 1 mg of guanfacine to take orally.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
Placebo: Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Guanfacine</title>
          <description>Guanfacine 1 mg capsule by mouth, one time prior to surgery.
Guanfacine: Patients will receive 1 mg of guanfacine to take orally.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
Placebo: Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="16.9"/>
                    <measurement group_id="B2" value="48.7" spread="15.4"/>
                    <measurement group_id="B3" value="45.3" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of PONV Score of Assessments Done at 15 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS)</title>
        <description>Comparison of PONV Score of assessments done at 15 minutes after arrival in PACU using the nVRS when 0 is no nausea and 10 is worst nausea</description>
        <time_frame>15 minutes after arriving in PACU</time_frame>
        <population>15 minute nVRS datapoint was not available for 2 participants in the Placebo group</population>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine</title>
            <description>Guanfacine 1 mg capsule by mouth, one time prior to surgery.
Guanfacine: Patients will receive 1 mg of guanfacine to take orally.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
Placebo: Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of PONV Score of Assessments Done at 15 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS)</title>
          <description>Comparison of PONV Score of assessments done at 15 minutes after arrival in PACU using the nVRS when 0 is no nausea and 10 is worst nausea</description>
          <population>15 minute nVRS datapoint was not available for 2 participants in the Placebo group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None (nVRS 0)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild (nVRS 1-5)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate/Severe (nVRS 6-10)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of PONV Score of Assessments Done at 30 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS)</title>
        <description>Comparison of PONV Score of assessments done at 30 minutes after arrival in PACU using the nVRS when 0 is no nausea and 10 is worst nausea</description>
        <time_frame>30 minutes after arriving in PACU</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine</title>
            <description>Guanfacine 1 mg capsule by mouth, one time prior to surgery.
Guanfacine: Patients will receive 1 mg of guanfacine to take orally.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
Placebo: Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of PONV Score of Assessments Done at 30 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS)</title>
          <description>Comparison of PONV Score of assessments done at 30 minutes after arrival in PACU using the nVRS when 0 is no nausea and 10 is worst nausea</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None (nVRS 0)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild (nVRS 1-5)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate/Severe (nVRS 6-10)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of PONV Score of Assessments Done at 60 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS)</title>
        <description>Comparison of PONV Score of assessments done at 60 minutes after arrival in PACU using the nVRS when 0 is no nausea and 10 is worst nausea</description>
        <time_frame>60 minutes after arriving in PACU</time_frame>
        <population>nVRS data was not available for 1 participant in the Guanfacine group</population>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine</title>
            <description>Guanfacine 1 mg capsule by mouth, one time prior to surgery.
Guanfacine: Patients will receive 1 mg of guanfacine to take orally.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
Placebo: Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of PONV Score of Assessments Done at 60 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS)</title>
          <description>Comparison of PONV Score of assessments done at 60 minutes after arrival in PACU using the nVRS when 0 is no nausea and 10 is worst nausea</description>
          <population>nVRS data was not available for 1 participant in the Guanfacine group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None (nVRS 0)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild (nVRS 1-5)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate/Severe (nVRS 6-10)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Nausea Assessment Using 11-point Nausea Scale (nVRS)</title>
        <description>PONV assessed using nVRS at 24 hours postop when 0 is no nausea and 10 is worst nausea.</description>
        <time_frame>24 hours post op</time_frame>
        <population>Only 70 patients (32 in guanfacine arm; 38 in placebo arm) responded to follow-up phone call and provided PONV data at the 24 hour timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine</title>
            <description>Guanfacine 1 mg capsule by mouth, one time prior to surgery.
Guanfacine: Patients will receive 1 mg of guanfacine to take orally.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
Placebo: Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Nausea Assessment Using 11-point Nausea Scale (nVRS)</title>
          <description>PONV assessed using nVRS at 24 hours postop when 0 is no nausea and 10 is worst nausea.</description>
          <population>Only 70 patients (32 in guanfacine arm; 38 in placebo arm) responded to follow-up phone call and provided PONV data at the 24 hour timepoint.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Postoperative Pain Assessment Using 11-point Visual/Verbal Analog (VAS)</title>
        <description>Maximum postoperative pain assessment assessed in PACU at 15, 30 and 60 minutes after PACU arrival using VAS when 0 is no pain and 10 is worst pain</description>
        <time_frame>15, 30, 60 minutes after arriving in PACU</time_frame>
        <population>Data unavailable for 2 participants in the placebo group at 15 minute time point, 1 participant in the placebo group at the 30 minute time point,</population>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine</title>
            <description>Guanfacine 1 mg capsule by mouth, one time prior to surgery.
Guanfacine: Patients will receive 1 mg of guanfacine to take orally.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
Placebo: Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Postoperative Pain Assessment Using 11-point Visual/Verbal Analog (VAS)</title>
          <description>Maximum postoperative pain assessment assessed in PACU at 15, 30 and 60 minutes after PACU arrival using VAS when 0 is no pain and 10 is worst pain</description>
          <population>Data unavailable for 2 participants in the placebo group at 15 minute time point, 1 participant in the placebo group at the 30 minute time point,</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>15 minutes after PACU admission</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None (Pain nVRS 0)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild (Pain nVRS 1-5)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate/Severe (Pain nVRS 6-10)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes after PACU admission</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None (Pain nVRS 0)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild (Pain nVRS 1-5)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate/Severe (Pain nVRS 6-10)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes after PACU admission</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None (Pain nVRS 0)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild (Pain nVRS 1-5)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate/Severe (Pain nVRS 6-10)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Pain Assessment Using 11-point Visual/Verbal Analog (VAS)</title>
        <description>Postoperative pain assessment using VAS at 24 hours postop when 0 is no pain and 10 is worst pain</description>
        <time_frame>24 hours postop</time_frame>
        <population>Based on only 71 participants to post operative questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine</title>
            <description>Guanfacine 1 mg capsule by mouth, one time prior to surgery.
Guanfacine: Patients will receive 1 mg of guanfacine to take orally.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
Placebo: Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Pain Assessment Using 11-point Visual/Verbal Analog (VAS)</title>
          <description>Postoperative pain assessment using VAS at 24 hours postop when 0 is no pain and 10 is worst pain</description>
          <population>Based on only 71 participants to post operative questionnaire.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Narcotic Requirement in PACU</title>
        <description>Total narcotic requirement in PACU tallied in morphine equivalents during PACU stay</description>
        <time_frame>Time frame between arrival and discharge in PACU, approximately 90 minutes</time_frame>
        <population>Data was not available for 1 participant in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine</title>
            <description>Guanfacine 1 mg capsule by mouth, one time prior to surgery.
Guanfacine: Patients will receive 1 mg of guanfacine to take orally.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
Placebo: Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Narcotic Requirement in PACU</title>
          <description>Total narcotic requirement in PACU tallied in morphine equivalents during PACU stay</description>
          <population>Data was not available for 1 participant in the placebo group.</population>
          <units>morphine equivalents</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.75" lower_limit="4.38" upper_limit="18.88"/>
                    <measurement group_id="O2" value="7.50" lower_limit="0.00" upper_limit="16.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Doses of PONV Treatment Administered in PACU</title>
        <time_frame>Time frame between arrival and discharge in PACU, approximately 90 minutes</time_frame>
        <population>Data missing for1 participants in the placebo group and 1 participant in the Guanfacine group.</population>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine</title>
            <description>Guanfacine 1 mg capsule by mouth, one time prior to surgery.
Guanfacine: Patients will receive 1 mg of guanfacine to take orally.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
Placebo: Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Doses of PONV Treatment Administered in PACU</title>
          <population>Data missing for1 participants in the placebo group and 1 participant in the Guanfacine group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Zero doses</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>One dose</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Two doses</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PACU Length of Stay in Minutes</title>
        <time_frame>Time frame between arrival and discharge in PACU, approximately 90 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine</title>
            <description>Guanfacine 1 mg capsule by mouth, one time prior to surgery.
Guanfacine: Patients will receive 1 mg of guanfacine to take orally.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
Placebo: Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.</description>
          </group>
        </group_list>
        <measure>
          <title>PACU Length of Stay in Minutes</title>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" lower_limit="95" upper_limit="169.5"/>
                    <measurement group_id="O2" value="110" lower_limit="87" upper_limit="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected from consent to discharge from PACU (about 7 hours)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Guanfacine</title>
          <description>Guanfacine 1 mg capsule by mouth, one time prior to surgery.
Guanfacine: Patients will receive 1 mg of guanfacine to take orally.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
Placebo: Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephen Harvey, MD</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>(615) 936-3198</phone>
      <email>stephen.harvey@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

